C4 Therapeutics (CCCC) PT Lowered to $22 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $3.18 +0.32%
Rating Summary:
11 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Rating Summary:
11 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
UBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $22.00 (from $24.00) while maintaining a Buy rating.
You May Also Be Interested In
- Insmed adds two independent directors with biopharma backgrounds
- Meta Platforms Inc. (META) PT Raised to $850 at Bernstein SocGen Group
- ARMOUR Residential (ARR) PT Lowered to $14.50 at B.Riley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
